PAPA JOSEPH C 4
4 · Emergent BioSolutions Inc. · Filed May 1, 2026
Research Summary
AI-generated summary of this filing
Emergent BioSolutions CEO Joseph Papa Receives 187,708 RSU Award
What Happened Joseph C. Papa, President, CEO and a director of Emergent BioSolutions Inc. (EBS), was granted 187,708 restricted stock units (RSUs) on April 29, 2026. The Form 4 reports the award as an acquisition (code A) at a grant price of $0.00 (i.e., an RSU award, not an open‑market purchase or sale). The RSUs represent the right to receive one share of common stock per unit when they vest.
Key Details
- Transaction date and type: 2026-04-29 — Grant/Award (Form 4 code A).
- Shares/units granted: 187,708 RSUs; reported grant price $0.00.
- Shares owned after transaction: not specified in the provided filing excerpt.
- Footnote highlights: the grant was approved by the Compensation Committee on March 2, 2026, conditioned on stockholder approval of an amendment to the 2006 Stock Incentive Plan; stockholders approved the amended plan on April 29, 2026. The RSUs vest in three annual installments beginning on the anniversary of the approval date, assuming continued service, and each RSU equals the right to one share (subject to adjustments).
- Filing timeliness: Form 4 filed 2026-05-01 for a 2026-04-29 transaction — appears timely under the Form 4 two‑business‑day rule.
Context Restricted stock units are compensation awards that convert to shares only as they vest; they are not an immediate cash purchase or sale. The economic value and any tax consequences to the insider depend on Emergent’s future share price at vesting and the terms of the grant agreement. This filing documents an executive compensation award rather than a market trade.
Insider Transaction Report
- Award
Common Stock
[F1][F2]2026-04-29+187,708→ 493,153 total
Footnotes (2)
- [F1]The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.
- [F2]Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.